Cervical Cancer Drugs Market, by Cancer Type (Squamous cell cancer and Adenocarcinoma), by Product Type (By Prevention (Cervarix, Gardasil 9, Recombinant Human Papillomavirus (HPV) Bivalent Vaccine, Recombinant Human Papillomavirus (HPV) Nonavalent Vaccine, Recombinant Human Papillomavirus (HPV) Quadrivalent Vaccine, and Others), by Treatment (Avastin, Bevacizumab, Bleomycin, Blenoxane, and Others)), by Distribution Channels (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies), and by Geography - Size, Share, Outlook, and Opportunity Analysis, 2018-2026

  • To Be Published : Dec 2019 |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Cervical cancer develops in women’s cervix, and mainly affects sexually active women aged between 30 and 45. Cervical cancer often shows no symptoms in early stages. However, the death rate of cervical cancer can be significantly reduced with use of Pap test (Papanicolaou test): a screening procedure which can detect the changes in the cervix before the cancer develops. There are different types of cervical cancer, out of which two main types are squamous cell cancer and adenocarcinoma.

Cervical Cancer Drugs Market Drivers

Increasing number of drug approval done by U.S. Food and Drug Administration (FDA) for the treatment of cervical cancer is expected to drive growth of the cervical cancer drugs market over the forecast period. For instance, in September 2017, U.S. Food and Drug Administration (FDA) approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer, which includes cervical, lung, brain, colorectal and kidney cancer. Mvasi is indicated for use in persistent, recurrent, or metastatic cervical cancer. In August 2014, U.S. FDA approved Genentech’s Avastin, which is bevacizumab solution for intravenous infusion in combination with paclitaxel for the treatment of persistent, recurrent, or metastatic cervical cancer.

Furthermore, increasing funding for cancer research, rising insurance coverage, and increase in the number of new targeted cancer drugs are expected to support the revenue growth of cervical cancer drugs market. For instance, National Cancer Institute, in 2015, spent around US$ 4,480 million on cancer research, which include cervical cancer, lung cancer, colorectal cancer, liver cancer, breast cancer, leukaemia, ovarian cancer, and uterine cancer. Furthermore, according to the American Cancer Society, U.S. invested around US$ 87.8 billion in 2014 on cancer research, in which the major cost accounting for around 44%, was paid by private insurance companies.

Increasing incidence of cervical cancer among the global population, rise in incidence of HIV in women, lack of awareness regarding the diagnosis for prevention of invasive cancer is expected to drive growth of the cervical cancer drugs market. Moreover, American cancer Society, in March 2018, funded around 22 grants for cervical cancer, which accounted for around US$ 9.3 million. The funding value is offered to a single or group of research, which includes a specific type of a cancer or area of cancer. For instance, according to Cancer Research UK, 2015 data findings, around 3,200 new cervical cancer cases were registered in the UK annually from 2013 to 2015.

Moreover, according to the same source, in 2015, cervical cancer accounted for around 2% of all cancer cases in females in the UK. A joint study conducted on cervical cancer by the Associated Chambers of Commerce and Industry of India (ASSOCHAM) and National Institute of Cancer Prevention and Research (NICPR), published in January 2018, reported that India alone has one fourth of the global burden of cervical cancer, which accounts for 17% of the all cancer deaths in women aged between 30 and 69 years in India. Moreover, according to the same source, it is estimated that around 1 in 53 Indian women are expected to be diagnosed by cervical cancer during their lifetime.

Cervical Cancer Drugs Market - Regional Analysis

Geographically, cervical cancer drugs market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America holds dominant position in cervical cancer drugs market, owing to increasing incidences of cervical cancer and growing research and development activities by various healthcare regulatory organizations in these region. For instance, according to the American Cancer Society’s (ACS) estimates for cervical cancer in the U.S. for 2018, around 13, 240 new cases of invasive cervical cancer were diagnosed and around 4,170 women are expected to die from cervical cancer. For instance, in 2013, Cervical Cancer-Free Coalition (CCFC) announced a collaborative research projects with funds ranging from US$ 5,000-US $10,000 each, which are focused on cervical cancer treatment in the U.S. 

Cervical Cancer Drugs Market Competitive Landscape

Some of the key players operating in the cervical cancer drugs market include F. Hoffmann-La Roche Ltd., Hetero, GlaxoSmithKline, plc, Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Pfizer, Inc., AstraZeneca plc, Allergan plc, Biocon Limited, Bristol-Myers Squibb Company, and Novartis AG. Key players operating in the market are focused on organic growth strategies, in order to enhance its market share and retain its competence in the market. For instance, in July 2014, MedImmune: a biologics research and development division of AstraZeneca entered into a clinical trial collaboration with Advaxis. According to the agreement, both companies conducted Phase I/II immunotherapy study to evaluate the safety and efficacy of MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor: MEDI4736, in combination with Advaxis’ cancer immunotherapy vaccine: ADXS-HPV. These study is conducted to develop treatment for patients with advanced, recurrent or refractory Human Papillomavirus (HPV)-associated cervical cancer.

Cervical Cancer Drugs Market Taxonomy:

By Cancer Type:

  • Squamous Cell Cancer
  • Adenocarcinoma

By Drug Type:

  • By Prevention
    • Cervarix
    • Gardasil 9
    • Recombinant Human Papillomavirus (HPV) Bivalent Vaccine
    • Recombinant Human Papillomavirus (HPV) Nonavalent Vaccine
    • Recombinant Human Papillomavirus (HPV) Quadrivalent Vaccine
    • Others
  • By Treatment
    • Avastin (Bevacizumab)
    • Bevacizumab
    • Bleomycin
    • Blenoxane (Bleomycin)
    • Others

By Distribution Channels:

  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Geography:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.